How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Pharmacovigilance Services Market
- By Service Type: Case Processing, Signal Detection and Risk Management, Aggregate Reporting, Regulatory Intelligence and Compliance, Medical Review and Literature Screening
- By End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Healthcare Providers, Regulatory Authorities, Medical Device Manufacturers
- By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Diseases, Autoimmune Disorders
- By Data Source: Spontaneous Reporting Systems, Clinical Trials, Electronic Health Records, Social Media and Digital Platforms, Literature and Scientific Publications
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Case Processing leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Pharmacovigilance Services Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
End User 5
Therapeutic Area 5
Data Source 5
Companies profiled
IQVIA
Parexel International Corporation
PPD (Pharmaceutical Product Development)
ICON plc
Covance Inc. (LabCorp)
Syneos Health
PRA Health Sciences
Charles River Laboratories
Pharmacovigilance Services by Accenture
Wipro Limited (Pharmacovigilance Services)
TCS (Tata Consultancy Services) Pharmacovigilance
Cognizant Technology Solutions (Pharmacovigilance)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →IQVIA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Parexel International Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →PPD (Pharmaceutical Product Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Covance Inc. (LabCorp)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Syneos Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PRA Health Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Charles River Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Pharmacovigilance Services by Accenture
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Wipro Limited (Pharmacovigilance Services)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →TCS (Tata Consultancy Services) Pharmacovigilance
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cognizant Technology Solutions (Pharmacovigilance)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sutherland Healthcare Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →ArisGlobal
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Medpace
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,822M by 2033 · 10.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Case Processing52.9
- Signal Detection and Risk Management15.4
- Aggregate Reporting11.5
- Regulatory Intelligence and Compliance12.1
- Medical Review and Literature Screening8.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$271.8M → $668.7M · 11.9%
Europe$189.5M → $398.7M · 9.7%
Asia Pacific$173.0M → $356.0M · 9.4%
Latin America$107.1M → $252.3M · 11.3%
Middle East and Africa$82.4M → $175.0M · 9.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.392026
10.402027
10.412028
10.422029
10.432030
10.442031
10.462032
10.482033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- IQVIA11.6
- Parexel International Corporation28.9
- PPD (Pharmaceutical Product Development)8.1
- ICON plc7.5
- Covance Inc. (LabCorp)10.7
- Syneos Health5.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type30.1%
End User29.1%
Therapeutic Area23.4%
Data Source17.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.1
- Europe21.5
- Asia Pacific19.2
- Latin America13.6
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| IQVIA | 86 | 74 | 94 | 82 | 90 | 75 | 84 |
| Parexel International Corporation | 82 | 74 | 78 | 75 | 90 | 72 | 79 |
| PPD (Pharmaceutical Product Development) | 72 | 77 | 65 | 88 | 66 | 85 | 76 |
| ICON plc | 69 | 67 | 68 | 64 | 79 | 72 | 70 |
| Covance Inc. (LabCorp) | 61 | 56 | 53 | 75 | 72 | 56 | 62 |
| Syneos Health | 63 | 52 | 49 | 70 | 48 | 63 | 58 |
| PRA Health Sciences | 53 | 50 | 64 | 65 | 58 | 65 | 59 |
| Charles River Laboratories | 43 | 52 | 40 | 37 | 47 | 52 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- IQVIA
- Parexel International Corporation
- PPD (Pharmaceutical Product Development)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| IQVIA | ✓ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Parexel International Corporation | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| PPD (Pharmaceutical Product Development) | ✓ | ◐ | − | ✓ | ◐ | ✓ |
| ICON plc | − | ◐ | ◐ | − | ◐ | ✓ |
| Covance Inc. (LabCorp) | − | ◐ | − | ✓ | ◐ | ◐ |
| Syneos Health | ◐ | − | ◐ | − | ◐ | ◐ |
| PRA Health Sciences | − | ◐ | ◐ | − | ◐ | ◐ |
| Charles River Laboratories | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1IQVIA84
2Parexel International Corporation79
3PPD (Pharmaceutical Product Development)76
4ICON plc70
5Covance Inc. (LabCorp)62
6PRA Health Sciences59
7Syneos Health58
8Charles River Laboratories45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
IQVIAParexel International Corporation
Challenger2
Strong scale, closing on the leaders.
PPD (Pharmaceutical Product Development)ICON plc
Contender3
Focused players with pockets of strength.
Covance Inc. (LabCorp)Syneos HealthPRA Health Sciences
Niche1
Specialists in a single segment or region.
Charles River Laboratories
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Pharmacovigilance Services Market — a $278M beachhead inside a $5.16B market.
Beachhead (SOM)$278Mobtainable near-term
Serviceable (SAM)$1.80Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Case Processing
Best fit — highest urgency & budget in Service Type.
Economic buyer80 fit
Signal Detection and Risk Management
Strong fit — clear ROI and a fast path to value.
End user65 fit
Aggregate Reporting
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Area
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel27%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pharmacovigilance Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified22%
Evaluation12%
Closed-won5%
$20.2KCAC
$104KLTV
5.1:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pharmacovigilance Services Market is a durable-growth opportunity — $5.12B by 2033, compounding at 6.1%.
TAM · 2025$3.20Btoday
TAM · 2033$5.12Bforecast
CAGR6.1%2027–2033
Cumulative$36.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.12BTotal addressable market
SAM$1.86BServiceable available market
SOM$309MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.1% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.12BLarge & growingTAM by 2033 at 6.1% CAGR
$1.86BServiceable nowreachable with today’s model
$309MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.00BBear3.9% CAGR
$5.12BBase6.1% CAGR
$6.56BBull8.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pharmacovigilance Services Market — a $7.03B market by 2033. Plan: grow share from 7.3% to 11.9%.
Market size · 2033$7.03Btotal addressable
Market CAGR5.8%2027–2033
Target share11.9%from 7.3% today
Revenue ambition$837Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 11.9% | At risk |
| Revenue | $549M | $837M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 28.3% | 39.9% | On track |
| Customer retention | 90.9% | 95.7% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $95M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pharmacovigilance Services Market conversation — a $1.48B market you can size, segment and defend in minutes.
Market size · 2033$1.48Btotal opportunity
Growth11.4%CAGR to 2033
Addressable buyers1,723+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 2 mopayback period
$71K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
IQVIAParexel International CorporationPPD (Pharmaceutical Product Development)ICON plcCovance Inc. (LabCorp)Syneos HealthPRA Health SciencesCharles River Laboratories+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pharmacovigilance Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pharmacovigilance Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Pharmacovigilance (PV) and Drug Safety Software Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportPharmacovigilance Outsourcing Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportPharma Contract Service Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportPharmacological Antidotes Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportPharmacokinetic Testing Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportPharmacokinetic Service Market
Market size, share, segmentation and regional forecast.
$673M market · 2025 base year
View reportPharmacokinetic Evaluation Market
Market size, share, segmentation and regional forecast.
$459M market · 2025 base year
View reportPharmacogenomics Technology (Theranostics & CDx) Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportPharmacogenomics Services Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportPharmacogenetics Testing Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportPharmacodynamic (PD) Biomarkers Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportPharmacodynamic Biomarker Testing Market
Market size, share, segmentation and regional forecast.
$407M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.